Bicara Therapeutics Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, Bicara Therapeutics stock has a consensus rating of "Buy" and an average price target of $31.46. The average 1-year stock price forecast is 28.15% higher than the current stock price, while the lowest is $16 (-34.83%) and the highest is $46 (+87.37%).

Price Target: $31.46 (+28.15%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$16	$31.46	$31	$46
Change	-34.83%	+28.15%	+26.27%	+87.37%

Analyst Ratings

The average analyst rating for Bicara Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	7	7	8	8	9	9
Buy	3	3	3	3	3	3
Hold	2	3	3	3	3	3
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	12	13	14	14	15	15

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Tazeen Ahmad Bank of America Securities	Bank of America Securities	Buy Maintains n/a	Buy	Maintains	n/a	n/a	Jun 2, 2026
Richard Law CFA Goldman Sachs	Goldman Sachs	Hold Maintains $16 → $18	Hold	Maintains	$16 → $18	-26.68%	Jun 2, 2026
Eva Fortea Verdejo Wells Fargo	Wells Fargo	Hold Reiterates $25 → $16	Hold	Reiterates	$25 → $16	-34.83%	Jun 2, 2026
Robert Burns H.C. Wainwright	H.C. Wainwright	Buy Reiterates $42	Buy	Reiterates	$42	+71.08%	Jun 1, 2026
Unknown Analyst Wedbush No rating	Wedbush	Buy Maintains $30	Buy	Maintains	$30	+22.20%	May 26, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-3.48

from -2.52

EPS Next Year

-3.63

from -3.48

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-
Operating Income	-37.66M	-39.89M	-82.39M	-155.60M	-237.90M
Net Income	-37.85M	-51.99M	-68.00M	-137.95M	-220.50M
EPS	-	-	-	-2.52	-3.48
Free Cash Flow	-	-32.50M	-53.72M	-66.40M	-194.67M
No. Analysts	-	-	-	-	13

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

EPS	2026	2027	2028
High	-2.52
Avg	-3.48
Low	-4.08

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-